In the European Union alone, several dozen new drugs are approved each year and tens of thousands of prescription drugs are on the market. Patent protection for pharmaceutically-active substances, formulations, and cosmetics continues to be of crucial economic importance for the pharmaceutical industry in order to secure a competitive edge.
The research and development of biologics and cell-based therapies is becoming increasingly important, but small-molecule drugs (small molecules) also continue to play a major role. Such trends have implications for how compounds can best be protected by patents.
Therefore, our firm continuously adapts its patent strategies to current market and research developments. In this way, we ensure that our clients receive competent support and advice in all relevant areas of the pharmaceutical and cosmetic industry.
Our patent attorneys in the field of pharma have extensive knowledge in all areas of therapeutically active substances, including biologics and "small molecules" and in diagnostic methods.
We advise and represent national and international clients in all fields of intellectual property, for example, in the following areas:
In the field of active pharmaceutical ingredients, we advise and represent both start-up companies and global pharmaceutical corporations - tailored to their individual needs.
Our firm drafts and files German and European patent applications, as well as supplementary protection certificates (SPCs). We represent clients before the German and European Patent Offices and coordinate grant proceedings worldwide.
Another focus of our work is the representation of our clients in opposition proceedings before the European Patent Office, as well as in national nullity proceedings before the German Federal Patent Court.
Furthermore, we provide legal opinions with respect to patent validity, patent infringement, and freedom-to-operate. In patent disputes before the German infringement courts, we collaborate with our experienced in-house attorneys, as well as our external partners.